China Myocardial Infarction Market Size, Share & Trends Analysis Report and Forecast, 2022-2028

China myocardial infarction (MI) market is estimated to grow modestly at a CAGR of around 7.6% during the forecast period. Increasing heart attacks in the country is projected to increase the myocardial infarction market in China. According to the WHO, CVD causes one-third of the total fatalities each year in China. As per the Institute for Health Metrics and Evaluation, the incidence of CVD is increasing continuously in the country. The incidence reached 13.5 million in 2017 as compared to 12.5 million in 2014. The country is expected to have a significant market share in the myocardial infarction treatment market. As per International Trade Administration, in 2018, the global medical device market is around 42% of the size of the pharmaceuticals market, however, in China, it is around 14% only, which express a significant growth potential of the sector. The medical device market is one of the fastest-growing markets in China with double-digit growth for over a decade.

Get Free Sample link @ https://www.omrglobal.com/request-sample/china-myocardial-infarction-market

The market is segmented into type, device, diagnosis, treatment, and end-user. Based on type, the market is segmented into ST-elevation myocardial infarction (STEMI) heart attacks, non-ST elevation myocardial infarction (NSTEMI) heart attacks, and silent heart attacks. Based on the device, the market is segmented into a left ventricular assist device, pacemaker, implantable cardioverter defibrillator, and others (aspiration-based catheters). Based on the diagnosis, the market is segmented into an electrocardiography (ECG), chest X-Ray, Computed Tomography (CT Scan), echocardiography, and others (blood test). Based on treatment, the market is segmented into medication and surgery. Based on end-user, the market is segmented into hospitals & clinics, Ambulatory Surgical Centers (ASCs), and research institutes.

A full report of China Myocardial Infarction Market available @ https://www.omrglobal.com/industry-reports/china-myocardial-infarction-market

  • Market Coverage
  • Market number available for – 2022-2028
  • Base year- 2021
  • Forecast period- 2022-2028
  • Segment Covered- By Source, By Product Type, By Applications
  • Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others

Market Segmentation

China Myocardial Infarction Market by Type

  • Non-ST-elevation myocardial infarction (NSTEMI)
  • ST-elevation myocardial infarction (STEMI)
  • Silent Heart Attacks

China Myocardial Infarction Market by Device          

  • Left Ventricular Assist Device (LVAD)
  • Pacemaker
  • Catheters
  • Implantable Cardioverter-Defibrillator (ICD)
  • Others (Stent Graft)

China Myocardial Infarction Market by Diagnosis   

  • Electrocardiography (ECG)
  • Chest X-Ray
  • Computed Tomography (CT Scan)
  • Echocardiography
  • Others (Blood Test)

China Myocardial Infarction Market by Treatment   

  • Medication
  • Analgesics
  • Thrombolytic
  • Antiplatelet Agents
  • Glycoprotein IIb/IIIa Inhibitors
  • Others (Beta-Adrenergic Blockers)
  • Surgery
  • Angioplasty
  • Bypass Surgery
  • Heart Transplant

China Myocardial Infarction Market by End-User

  • Hospital & Clinics
  • Ambulatory Surgical Centers
  • Research Institutes

Company Profiles

  • Abbott Laboratories Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Boston Scientific Corp.
  • Bristol-Myers Squibb Co.
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services, Inc.
  • Lifetech Scientific Corp.
  • Medtronic PLC
  • Merck KGaA
  • Mylan N.V.
  • Novartis AG
  • Pfizer Inc.
  • Siemens AG

The Report Covers

  • Comprehensive research methodology of the China myocardial infarction market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the China myocardial infarction market.
  • Insights about market determinants which are stimulating the China myocardial infarction market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/china-myocardial-infarction-market

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: info@omrglobal.com

Contact no: +91 780-304-0404